Sabine D. Brookman-May
@brookmans76
Professor of Urology @LMU_Muenchen, Vice President R&D Bladder Cancer, @JNJInnovMed, GU Oncology, Sports Medicine 🚵♀️Passionate Cyclist
ID:1206131683
21-02-2013 22:06:03
1,0K Tweets
2,6K Followers
2,2K Following
Leaving Valencia after European Association of Urology (EAU) #EAUTalentIncubator module 2. A great opportunity to share experience and knowledge on aspects of wellbeing + how it affects work efficiency, and to learn from Jason Howlett, Nick Raison, Eamonn Rogers. A great program again!@JLVasquez82 EAU Young Urologists
Sabine D. Brookman-May gives insights into strategic use of data collection and interpretation to inspire behavior change and contribute to positive outcomes in performance ⌚️❤️😴 #EAUTalentIncubator 💪🏾🌱 EAU Young Urologists
📬 Finally out in The Lancet Oncology the results from Cohort B of KN057 trial. Pembro in BCG-unresponsive papillary tumors w/out Cis. 43% 12m DFS adds a Rx piece to the literature. Now included in National Comprehensive Cancer Network (NCCN) guidelines. Congrats Ashish M. Kamat, MD, MBBS Petros Grivas & team! sciencedirect.com/science/articl…
Diversity and global representation at its best in the IBCG Amer. Urol. Assn. #AUA -IBCG #Bladderca forum!
Ashish M. Kamat, MD, MBBS Joan Palou Redorta Petros Grivas Janet Kukreja Karima Oualla, MD,MSc Prof Param Mariappan Petros Grivas Chiara Mercinelli Andrea Necchi Philippe spiess
Getting MoonRISe1 started with Roger Li and Benjamin Pradere on board is the best kick-off and basis for a study on #TAR210 in #FGFR + IR #NIMBC #BladderCancer
Great work Josh Linscott Roger Li presented at #AUA2024
➡️ Mutations detected by #utDNA concordant with bladder tumor
➡️ Range from single point mutations to chromosomal loss/gain
➡️ Possible tool for MRD detection in #NMIBC
Moffitt Cancer Center #BladderCancer
A really great session at #AUA24
Thank you #IBCG Ashish M. Kamat, MD, MBBS for an excellent agenda, great debates and speakers #BladderCancer
Beyond others Arnulf Stenzl Petros Grivas debating the need of RC in cT0 after NAC/NIO
👉biomarkers/ctDNA/MRI may help to select pts, but more evidence needed
Can we settle the debate about #PLND at RC in #BladderCancer ?
✅ Seth Lerner sharing arguments for SLND instead ELND based on S1011 and LEA studies
🚫Sia Daneshmand, M.D. Outcomes might still get improved with extended LND, especially in selected patients (eg ctDNA+)
#AUA24 #IBCG
Excellent talks Sarah P. Psutka MD MS and Prof Param Mariappan on disease management of LG IR #NMIBC
Are #chemoablation , fulguration, #ActiveSurveillance proper options? A risk adapted approach based on rigorous diagnosis and #IBCG risk criteria might be most recommendable #AUA24 #BladderCancer
To do or not to do - Re- #TURBT ? Supporting arguments on both sides Jeremy Teoh and Badrinath Konety, MD, MBA “Do it right the first time” (Jeremy Teoh) or despite that still needed? #BladderCancer
Antoni Vilaseca presenting updated data on #TAR210 FIH study in patients with #FGFR + #NMIBC today at #AUA24
✅90% estimated 12 months RFS in BCG experienced HR NMIBC
✅90% CR in IR NMIBC
#BladderCancer Johnson & Johnson Innovation #MyCompany #Erdafitinib
Updated data from Sunrise1 #TAR200 study presented by Joe Jacob MD, MCR in patients with CIS +/-papillary HR #NMIBC #AUA24
✅ 82.8% Complete Response (CR) rate per central review/86.2% per local assessment
✅ 98% of CRs were achieved within 12 weeks
Johnson & Johnson Innovation #MyCompany #MyTeam
#SethLerner presenting data from #SWOGS1011 on standard vs extended #LND at time of #RadicalCystectomy
👉No benefit for ELND compared to SLND in terms of OS or DFS
👉ELND associated with higher morbidity and peri-operative mortality
#AUA24 #BladderCancer
Comprehensive summary by Todd 〽️ Morgan, MD of updated Amer. Urol. Assn. AUA guidelines on decision making at #BCR after RP #ProstateCancer highlighting the need to consider risk factors and the role of #PSMAPET #AUA24 #SalvageRT
Started #AUA24 with a full day dedicated to AUA Innovation Nexus
Great meeting to initiate exchange between #Pharma , #biotechs and #startups with the focus on urology/medical technology led by an experienced urological entrepreneur Dr. Steven Kaplan Amer. Urol. Assn.